GRACE LIFE-TECH (02112) announced its interim results for 2025, reporting revenue of US$8.417 million, representing a 41% year-on-year increase. The company recorded a profit attributable to owners of the parent company of US$211,000, compared to a loss of US$8.966 million in the same period last year. Basic earnings per share stood at 0.01 US cents. The increase in sales revenue during the period was attributed to the expansion of plant stem cell sales channels and growth in customer base.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.